Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: From the NHLBI dynamic registry

American Journal of Cardiology

Volumn 111, Issue 4, 2013, Pages 486-492

  Mulukutla, Suresh R ^a   Marroquin, Oscar C ^a   Vlachos, Helen A ^a   Selzer, Faith ^a   Toma, Catalin ^a   Kip, Kevin E ^b   Abbott, J Dawn ^c   Holper, Elizabeth ^d   Lee, Joon S ^a   Khandhar, Sameer ^a   Kutcher, Michael ^e   Kelsey, Sheryl ^a   Smith, Conrad ^a   Faxon, David ^f   Williams, David O ^f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DEATH; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG ELUTING STENT; DUAL ANTI PLATELET THERAPY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPIRIN; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84873295229     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.10.030     Document Type: Article

References (27)

1. S.B. King III, S.C. Smith Jr., J.W. Hirshfeld Jr., A.K. Jacobs, D.A. Morrison, D.O. Williams, 2005 Writing Committee Members, T.E. Feldman, M.J. Kern, W.W. O'Neill, H.V. Schaff, P.L. Whitlow, C.D. Adams, J.L. Anderson, C.E. Buller, M.A. Creager, S.M. Ettinger, J.L. Halperin, S.A. Hunt, H.M. Krumholz, F.G. Kushner, B.W. Lytle, R. Nishimura, R.L. Page, B. Riegel, L.G. Tarkington, and C.W. Yancy 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 2008 261 295
2. C.L. Grines, R.O. Bonow, D.E. Casey Jr., T.J. Gardner, P.B. Lockhart, D.J. Moliterno, P. O'Gara, and P. Whitlow Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians Circulation 115 2007 813 818
3. F. Airoldi, A. Colombo, N. Morici, A. Latib, J. Cosgrave, L. Buellesfeld, E. Bonizzoni, M. Carlino, U. Gerckens, C. Godino, G. Melzi, I. Michev, M. Montorfano, G.M. Sangiorgi, A. Qasim, A. Chieffo, C. Briguori, and E. Grube Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 2007 745 754
4. S.C. Smith Jr., T.E. Feldman, J.W. Hirshfeld Jr., A.K. Jacobs, M.J. Kern, S.B. King III, D.A. Morrison, W.W. O'Neill, H.V. Schaff, P.L. Whitlow, D.O. Williams, E.M. Antman, C.D. Adams, J.L. Anderson, D.P. Faxon, V. Fuster, J.L. Halperin, L.F. Hiratzka, S.A. Hunt, R. Nishimura, J.P. Ornato, R.L. Page, and B. Riegel ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 113 2006 156 175
5. W.K. Laskey, C.W. Yancy, and W.H. Maisel Thrombosis in coronary drug-eluting stents: report from the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health Circulation 115 2007 2352 2357
6. F. Saia, A. Marzocchi, and A. Branzi Review: the safety of drug-eluting stents Ther Adv Cardiovasc Dis 2 2008 43 52
7. A.T. Ong, A. Hoye, J. Aoki, C.A.G. van Mieghem, G.A. Rodriguez Granillo, K. Sonnenschein, and E. Regar Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation J Am Coll Cardiol 45 2005 947 953
8. A.T. Ong, E.P. McFadden, E. Regar, P.P. de Jaegere, R.T. van Domburg, and P.W. Serruys Late angiographic stent thrombosis (LAST) events with drug-eluting stents J Am Coll Cardiol 45 2005 2088 2092
9. E. Regar, P.A. Lemos, F. Saia, M. Degertekin, K. Tanabe, C.H. Lee, C.A. Arampatzis, A. Hoye, G. Sianos, P. de Feyter, W.J. van der Giessen, P.C. Smits, R.T. van Domburg, and P.W. Serruys Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients Am J Cardiol 93 2004 1271 1275
10. I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic, F. Airoldi, A. Chieffo, M. Montorfano, M. Carlino, I. Michev, N. Corvaja, C. Briguori, U. Gerckens, E. Grube, and A. Colombo Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
11. B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindback, T. Nilsson, and L. Wallentin Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
12. E.L. Eisenstein, K.J. Anstrom, D.F. Kong, L.K. Shaw, R.H. Tuttle, D.B. Mark, J.M. Kramer, R.A. Harrington, D.B. Matchar, D.E. Kandzari, E.D. Peterson, K.A. Schulman, and R.M. Califf Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
13. S.J. Park, D.W. Park, Y.H. Kim, S.J. Kang, S.W. Lee, C.W. Lee, K.H. Han, S.W. Park, S.C. Yun, S.G. Lee, S.W. Rha, I.W. Seong, M.H. Jeong, S.H. Hur, N.H. Lee, J. Yoon, J.Y. Yang, B.K. Lee, Y.J. Choi, W.S. Chung, D.S. Lim, S.S. Cheong, K.S. Kim, J.K. Chae, D.Y. Nah, D.S. Jeon, K.B. Seung, J.S. Jang, H.S. Park, and K. Lee Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
14. M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz, F. Castriota, F. Colombo, M. Tebaldi, G. Fucà, M. Kubbajeh, E. Cangiano, M. Minarelli, A. Scalone, C. Cavazza, A. Frangione, M. Borghesi, J. Marchesini, G. Parrinello, and R. Ferrari Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
15. S.S. Brar, J. Kim, S.K. Brar, R. Zadegan, M. Ree, I.L.A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A.Y.J. Shen Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions J Am Coll Cardiol 51 2008 2220 2227
16. O.C. Marroquin, F. Selzer, S.R. Mulukutla, D.O. Williams, H.A. Vlachos, R.L. Wilensky, J.F. Tanguay, E.M. Holper, J.D. Abbott, J.S. Lee, C. Smith, W.D. Anderson, S.F. Kelsey, and K.E. Kip A comparison of bare-metal and drug-eluting stents for off-label indications N Engl J Med 358 2008 342 352
17. D.H. Shin, I.H. Chae, T.J. Youn, S. Cho, D.A. Kwon, J.W. Suh, H.J. Chang, Y.S. Cho, W.Y. Chung, Y.J. Choi, H.C. Gwon, K.R. Han, and D.J. Choi Reasonable duration of Clopidogrel use after drug-eluting stent implantation in Korean patients Am J Cardiol 104 2009 1668 1673
18. L. Mauri, T.S. Silbaugh, R.E. Wolf, K. Zelevinsky, A. Lovett, Z. Zhou, F.S. Resnick, and S.T. Normand Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts Circulation 118 2008 1817 1827
19. M.H. Shishehbor, S.S. Goel, S.R. Kapadia, D.L. Bhatt, P. Kelly, R.E. Raymond, J.M. Galla, and S.J. Brener Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality J Am Coll Cardiol 52 2008 1041 1048
20. M.C. Morice, P.W. Serruys, P. Barragan, C. Bode, G.A. VanEs, H.P. Stoll, D. Snead, L. Lauri, D.E. Cutlip, and E. Sousa Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial J Am Coll Cardiol 50 2007 1299 1304
21. J.L. Petersen, J.J. Barron, B.G. Hammill, M.J. Cziraky, K.J. Anstrom, P.M. Wahl, E.L. Eisenstein, M.W. Krucoff, R.M. Califf, K.A. Schulman, and L.H. Curtis Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database Am Heart J 159 2010 462 470
22. J.A. Spertus, R. Kettelkamp, C. Vance, C. Decker, P.G. Jones, J.S. Rumsfeld, J.C. Messenger, S. Khanal, E.D. Peterson, R.G. Bach, H.M. Krumholz, and D.J. Cohen Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 113 2006 2803 2809
23. S.R. Steinhubl, P.B. Berger, J.T. Mann III, E.T. Fry, A. DeLago, C. Wilmer, E.J. Topol CREDO Investigators Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
24. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, K. Malmberg, H. Rupprecht, F. Zhao, S. Chrolavicius, I. Copland, K.A. Fox CURE Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
25. H.D. Aronow, S.R. Steinhubl, D.M. Brennan, P.B. Berger, and E.J. Topol Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 157 2009 369 374
26. P.B. Berger, D.L. Bhatt, V. Fuster, G. Steg, K.A.A. Fox, M. Shao, D.M. Brennan, W. Hacke, G. Montalescot, S.R. Steinhubl, and E.J. Topol Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial Circulation 121 2010 2575 2583
27. United States Food and Drug Administration. The Dual Antiplatelet Therapy study: critical path drives unique collaboration to improve patient safety. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/SpotlightonCPIProjects/ucm171900.htm. Accessed November 19, 2012.